Phase II SBIR Grant

The Fox Chase Chemical Diversity Center Announces that it Has Been Awarded a Phase II SBIR Grant, “Development of Small Antimicrobial Peptide Mimics,” Totaling $2,000,000. Doylestown, PA. August 23, 2013- FCCDC is pleased to announce that is has been...

Small Business Phase I STTR Grant

The Fox Chase Chemical Diversity Center Announces that it Has Been Awarded a Small Business Phase I STTR Grant Entitled DC-SIGN Inhibitors for the Treatment of HIV Infection for $300,000. Doylestown, PA. July 22, 2013- FCCDC is pleased to announce that it has...

FCCDC To Conduct Medicinal Chemistry Efforts

The Fox Chase Chemical Diversity Center Announces that Promentis Pharmaceuticals Inc Has Engaged FCCDC To Conduct Medicinal Chemistry Efforts. Doylestown, PA. June 27, 2013- FCCDC is pleased to announce that Promentis Pharmaceuticals, Inc,a private, emerging...

2-Year Phase II SBIR Totaling $1,919,714

The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a 2-Year Phase II SBIR Grant Totaling $1,919,714.00 Doylestown, PA. June 24, 2013- FCCDC is pleased to announce that it has been awarded a 2-year Phase II SBIR grant (R44 CA156781-02) totaling...